No Data
No Data
No Data
No Data
No Data
Arcutis Biotherapeutics(ARQT.US) Officer Sells US$40,901.64 in Common Stock
$Arcutis Biotherapeutics(ARQT.US)$ Officer Moore Matthew Richard sold 4,681 shares of common stock on May 2, 2024 at an average price of $8.7378 for a total value of $40,901.64.Source: Announcement Wh
Futu NewsMay 4 05:11
Form 144 | Arcutis Biotherapeutics(ARQT.US) Officer Proposes to Sell 120.43K in Common Stocks
SEC FILLINGS DISCLOSED/ May 2, $Arcutis Biotherapeutics(ARQT.US)$ Officer Watanabe Todd Franklin intends to sell 13,783 shares of its common stock on May 2, with a total market value of approximately
Futu NewsMay 3 03:36
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
GlobeNewswireApr 30 04:00
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Shareholders in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The consensus estimated reven
Simply Wall StApr 26 18:18
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)
TipRanksApr 22 14:50
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $16 Price Target
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.
BenzingaApr 12 18:44
No Data
No Data